Aurora Cannabis Inc. and Namaste Technologies Inc. announced the signing of a binding term sheet towards a final Private-Label Software Agreement whereby Namaste will provide Aurora's wholly-owned subsidiary, CanvasRx Inc. with a customized version of Namaste's patient acquisition tool, NamasteMD.com, as well as desktop and mobile applications for Google Android and Apple iOS platforms. The companies have 30 days to complete a final agreement. Under the terms of the Private Label Agreement: Namaste will provide CanvasRx with a customized, CanvasRx-branded version of NamasteMD; Namaste will provide CanvasRx with a two-year exclusivity period for the private label version of NamsteMD.com in Canada; Namaste will initially provide the application for both the Google Android and Apple iOS platforms; CanvasRx will require their own doctors and/or nurse practitioners to operate the platform; commercial terms of the agreement are not disclosed; and in consideration of Aurora's assistance for the future optimization of NamasteMD, Namaste has issued Aurora 500,000 stock options, exercisable at $3.35 per common share for 48 months, vesting quarterly over 12 months. In addition, the companies have also signed a non-binding, non-exclusive Letter of Intent to complete a final Consultation & Support Services Agreement, whereby Namaste will provide patient referral services to Aurora, where applicable under Canada's Access to Cannabis for Medical Purposes ("ACMPR") regulations. Under the terms of the Consultation Agreement: Namaste shall provide certain patient-focused education and strain selection services, as well as assistance in preparing the requisite paperwork (Medical Documentation) for registering patients with Aurora; the Agreement is non-exclusive for a one-year term; Namaste shall provide the services under the agreement on preferential terms to Aurora; and commercial terms of the Consultation Agreement are not disclosed.